Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning

  title={Allogeneic Haemopoietic Stem Cell Transplantation for Multiple Myeloma or Plasma Cell Leukaemia Using Fractionated Total Body Radiation and High-dose Melphalan Conditioning},
  author={Nigel Russell, Eric Bessell, Claire Stainer, Andrew Hayn},
  journal={Acta Oncologica},
  pages={837 - 841}
We have evaluated the outcome of allogeneic haemopoietic stem cell transplantation for multiple myeloma using a conditioning regimen comprising fractionated total body irradiation and high-dose melphalan (110 mg/m2). The study comprised 25 patients (median age 49 years) who had been transplanted by either bone marrow (n = 13) or G-CSF mobilized peripheral blood stem cells (n = 12). Overall transplant-related mortality was 30% but was lower for patients <50 years of age at transplant (21%). The… 
2 Citations
Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma.
  • S. HolsteinV. Suman P. McCarthy
  • Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2020
Biotechnology: Discoveries and Their Applications in Societal Welfare
The present chapter describes the field of biotechnology from earliest known mention till modern-day developments. The introduction throws light on understanding the practice of using microorganisms


Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.
Using both bone marrow and PBSC together with GM-CSF, autotransplants are safe and appear effective in myeloma, especially when prior therapy had been limited to less than 1 year.
Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma
It is suggested that PBSC may improve the therapeutic efficacy of allogeneic transplant in MM, not only by a reduction of TRM but also by an improvement of rate and quality of response.
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and beta-2-microglobulin.
Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome.
It is indicated that allografting for patients with MM can result in long-term disease-free survival for a minority of patients, and efforts to reduce transplant-related mortality should focus on earlier transplantation, less toxic treatment regimens, better supportive care, and improved prevention and treatment of graft-versus-host disease (GVHD).
Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors.
Immunoglobulin gene fingerprinting, a PCR-based technique, is used to evaluate minimal residual disease in 5 patients in unmaintained CR 9-60 months after allogeneic BMT, suggesting that cure of multiple myeloma may be a realistic goal.
Impact of previous high-dose therapy on outcome after allografting for multiple myeloma
It is concluded that since allogeneic bone marrow transplantation is the only potentially curative option in myeloma, it should be offered to younger patients early in the course of their disease, when procedure-related morbidity and mortality are likely to be at their lowest.
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
  • G. GahrtonS. Tura P. Jacobs
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma
VAD/IDM is an effective and safe induction therapy for autologous and allogeneic stem cell transplantation in newly diagnosed multiple myeloma and well known prognostic factors were not significant for response or survival.
Criteria for evaluating disease response and progression in multiple myeloma treated with high dose chemotherapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT
  • Br J Haematol
  • 1998